Enoblituzumab, previously known as TJ-271 or MGA271, represents an unique therapeutic targeting CD33, the marker found predominantly on myeloid tissues. This molecule functions as the two-pronged therapy, at once https://www.targetmol.com/compound/enoblituzumab